Two case reports and literature review for hepatic epithelioid angiomyolipoma: Pitfall of misdiagnosis

Jia-Xi Mao, Fei Teng, Cong Liu, Hang Yuan, Ke-Yan Sun, You Zou, Jia-Yong Dong, Jun-Song Ji, Jun-Feng Dong, Hong Fu, Guo-Shan Ding, Wen-Yuan Guo

Abstract

BACKGROUND
Hepatic epithelioid angiomyolipoma (HEAML) is a rare liver disease and is easily misdiagnosed. Enhanced recognition of HEAML is beneficial to the differential diagnosis of rare liver diseases.

CASE SUMMARY
We presented two cases of HEAML in Changzheng Hospital, Naval Medical University, and then collected and analyzed all reports about HEAML recorded in PubMed, MEDLINE, China Science Periodical Database, and VIP database from January 2000 to March 2018. A total of 409 cases of HEAML in 97 reports were collected, with a ratio of men to women of 1:4.84 and an age range from 12 years to 80 years (median 44 years). Among the patients with clinical symptoms mentioned, 61.93% (205/331) were asymptomatic, 34.74% (115/331) showed upper or right upper quadrant abdomen discomfort, while a few of them showed abdominal mass, gastrointestinal symptoms, low fever, or weight loss. The misdiagnosis rate of HEAML was as high as 40.34% (165/409) due to its nonspecific imaging findings. Most of the tumors were solitary and round in morphology, with clear boundaries. Ultrasound scan indicated low echo with internal nonuniformity and rich blood supply in most cases. Computer tomography/magnetic resonance imaging enhanced scan showed varied characteristics. The ratio of fast wash-in and fast wash-out, fast wash-in and slow wash-out, and delayed enhancement was roughly 4:5:1. A definite diagnosis of HEAML depended on the pathological findings of the epithelioid cells in lesions and the expression of human melanoma black 45, smooth muscle actin, melanoma antigen, and actin by immunohistochemical staining. HEAML had a relatively low malignant rate of 3.91%. However, surgical resection was the main method of treatment for HEAML.
CONCLUSION
HEAML is a rare and easily misdiagnosed disease, and it should be diagnosed carefully, taking into account clinical course, imaging, pathological, and immunohistochemical findings.

Key words: Hepatic epithelioid angiomyolipoma; Imaging; Pathology; Misdiagnosis; Potentially malignant; Case report

© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

INTRODUCTION
Hepatic epithelioid angiomyolipoma (HEAML) is a rare subtype of hepatic angiomyolipoma (AML). It is a hepatic mesenchymal neoplasm with malignant potential that is primarily composed of epithelioid cells. Retrieved from major databases, a total of 409 cases of HEAML have been reported with a misdiagnosis rate as high as 40.34% (165/409) due to its non-specific manifestations. Here we presented two cases of HEAML in Changzheng Hospital, Naval Medical University, Shanghai and made pooled analysis on the diagnosis and prognosis of HEAML. This work was performed in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of Changzheng Hospital. Written informed consents were obtained from the 2 patients for using their data for clinical research and publication.

CASE PRESENTATION

Case 1
History and physical examination: A 40-year-old female patient was admitted to hospital because 'health examination revealed hepatic space-occupying lesion 1 wk ago'. The patient had no obvious positive clinical manifestations and positive signs.

Diagnostic imaging: Ultrasound and computed tomography (CT) scan suggested a mass of 5 cm × 3 cm in the right lobe of liver (Figure 1A). The hepatitis B surface antigen and tumor markers, such as alpha fetoprotein (AFP), carcino-embryonic antigen (CEA), carbohydrate antigen (CA) 199, and CA125, were all negative.

Histopathology: The postoperative pathological diagnosis was HEAML (potentially malignant) (Figure 1B-C). Immunohistochemistry results were as follows: Antigen Ki67 (Ki67) (1% positive), human melanoma black 45 (HMB45) (positive in some cells), smooth muscle actin (SMA) (weak positive), soluble protein-100 (S100) (-), cluster of differentiation (CD) 34 (positive in vessels), calponin (++) (Figure 1D), estrogen receptor (positive in some cells) (Figure 1E), progesterone receptor (+) (Figure 1F), Keratin-pan (Kpan) (weak positive) (Figure 1G), epithelial membrane antigen (EMA) (-), vimentin (partially positive) (Figure 1H), neuron-specific enolase (-)
Figure 1  Imaging and pathological immunohistochemical findings of case 1. A: Computed tomography scan suggested a mass of 5 cm × 3 cm in the right lobe of liver; B, C: The postoperative pathological diagnosis was hepatic epithelioid angiomyolipoma (HE staining, B: × 100, C: × 400); D-I (× 200): Immunohistochemistry results were as follows: Calponin (++) (D); estrogen receptor (positive in some cells) (E); progesterone receptor (+) (F); K-pan (weak positive) (G); vimentin (partially positive) (H); and actin (partially positive) (I). HE: Hematoxylin and eosin.

Case 2

History of illness: A 39-year-old female patient underwent left nephrectomy due to a left kidney space-occupying lesion in October, 2009. Postoperative pathological examination suggested epithelioid AML. In April 2010, abdominal CT revealed left retroperitoneal lymph node enlargement, which was biopsied afterwards by surgery. Pathological examination prompted a diagnosis of AML. The patient was treated by radiotherapy and high intensity focused ultrasound during the next few years but did not achieve a complete cure.

Imaging examination, histopathology: In routine review on 8 July 2014, ultrasound and CT scan revealed a mass with a maximum diameter of about 6 cm in liver. A CT-guided liver tumor puncture biopsy was performed (Figure 2A), and the pathological diagnosis suggested metastatic HEAML (Figure 2B-D). Immunohistochemistry results were as follows: Ki67 (1% positive), HMB45 (+), melanoma antigen (Melan-A) (+), SMA (+), S100 (-), EMA (-), vimentin (partially positive), AFP (-), and HepPar-1 (-). On 25 July 25 2014, chest CT revealed multiple micronodules in the right lung, the largest one of which was approximately 4 mm and located in the superior lobe.
Figure 2 Computed tomography guided percutaneous liver tumor puncture and pathological findings of case 2. A: Computed tomography scan revealed a mass of 3.5 cm × 3.0 cm in liver; B-D: The pathological diagnosis suggested metastatic hepatic epithelioid angiomyolipoma (HE staining, B: × 100, C: × 200, D: × 400).

FINAL DIAGNOSIS

Case 1
The patient was diagnosed with primary HEAML.

Case 2
This patient was diagnosed as a secondary HEAML of renal origin.

TREATMENT

Case 1
The patient underwent liver resection on the third day after admission. During intraoperative exploration, a mass with medium texture and clear boundaries was found located in segment 6, protruding from the liver surface, while no satellite lesions were discovered.

Case 2
The patient underwent transcatheter arterial chemoembolization six times between 28 July 2014 and 10 March 2016. During that period, chest CT and abdominal magnetic resonance imaging (MRI) was performed repeatedly and confirmed the presence of bilateral lung nodules, liver space-occupying lesion, and retroperitoneal lymph node enlargement.

OUTCOME AND FOLLOW-UP

Case 1
The patient recovered well after surgery and was discharged on the postoperative day 9. There was no relapse during the 3 years of follow-up.

Case 2
The patient ultimately died on 15 October 2016 due to systemic metastasis of the tumor and multiple organ failure.
DISCUSSION

Literature review

General data: We collected all reports related to HEAML recorded in the PubMed, MEDLINE, China Science Periodical Database, and VIP database from January 2000 to March 2018. A total of 64 articles were enrolled into analysis after excluding 32 articles without valuable data and five articles with repeated data [1-64]. In total, there were 409 cases, of which 386 presented as single tumor and 23 presented as multiple tumors. The male to female ratio was 1:4.84, with 70 males and 339 females. The median age was 44 years old, ranging from 12 years to 80 years old. Of the patients with symptoms mentioned in articles, 61.93% (205/331) were asymptomatic when ultrasound or imaging examination discovered the tumors, while 34.74% (115/331) present with discomfort of the upper abdomen. Fourteen patients had a history of hepatitis B. Seven patients had tuberous sclerosis complex (TSC). The aminotransferases were abnormal in 4 patients. The CA199 level was elevated in 4 patients. Two patients had a history of breast cancer, while one patient was comorbid with cholangiocarcinoma and had elevated CA125 level. Two patients were comorbid with hepatic hemangiomia, one patient was comorbid with gallstone disease, and one patient was comorbid with cirrhosis due to schistosomiasis.

The tumor was located in the right lobe in 181 cases, left lobe in 153 cases, and caudate lobe in 12 cases. The maximum diameter of the tumor ranged from 1 cm to 20 cm, with a median of 5.9 cm. Among the cases with tumor morphology described, tumors were round in 86 cases (85.15%) and lobular or irregular in 15 cases (14.85%), while tumors were well defined in 116 cases (84.67%) and ill-defined in 21 cases (15.33%).

Ultrasonography: Ultrasound usually indicated low echo on HEAML, with clear boundary, internal nonuniformity, and rich blood supply. A low echo halo presented in 27.66% cases (13/47). Contrast-enhanced ultrasonography revealed that all lesions appeared homogeneous hyperechoic during arterial phase, and most lesions appeared homogeneous isoechoic during portal and delayed phase (Table 1).

CT: HEAML mostly showed as slightly low density with nonuniformity on CT plain scan. The lesions were obviously or moderately enhanced in arterial phase, and the enhancement decreased during portal and delayed phase in most cases. The enhanced scan showed varied characteristics. The ratio of fast wash-in and fast wash-out, fast wash-in and slow wash-out, and delayed enhancement was roughly 4:5:1. The central vessel sign could be seen in 75.80% of the cases (119/157), and the early drainage veins, which returned into branches of hepatic vein or portal vein, could be seen in 61.48% of the cases (75/122). HEAML usually had no capsule. When the tumor was large enough, it might oppress the surrounding liver parenchyma to form an incomplete pseudocapsule (Table 2).

MRI: MRI scan usually suggested inhomogenous and low T1 weighted imaging (T1WI) signal and an increase in T2WI and diffusion weighted imaging (DWI) signal. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced scan usually showed marked enhancement in the arterial phase, which was decreased during portal and delayed phase (Table 3).

Diagnosis and treatment: Preoperative diagnosis of HEAML was difficult. Among the 409 cases, 59 cases were preoperatively misdiagnosed as benign diseases, including 16 cases of focal nodular hyperplasia, 15 cases of hepatocellular adenoma (HCA), 11 cases of AML, five cases of hemangiomas, one case of hamartoma, and 11 cases of unclassified tumors. One hundred and four cases were misdiagnosed as malignant diseases, including 71 cases of hepatocellular carcinoma, one case of cholangiocarcinoma, five cases of metastatic cancer, three cases of mesenchymal tissue-derived tumors (angiosarcoma, liposarcoma, etc), and 24 cases of unclassified tumors. Another two cases were not diagnosed clearly preoperatively. The misdiagnosis rate was thus as high as 40.34% (165/409). Surgical resection was the main treatment for HEAML, due to the difficulty diagnosing before operation. For those not suitable for hepatectomy, ablation or interventional therapy could be the alternative treatment after puncture biopsy for pathological diagnosis.

Gross appearance: In general, the section of HEAML was incanus and grayish yellow or grayish red, and the texture was soft mostly. Most of the HEAML had no capsule, with clear or relatively clear boundaries. For HEAMLs, 40.27% (60/149) were accompanied by hemorrhage and necrosis, and 33.33% (23/69) were comorbid with fat lesions. Cystic degeneration occurred in 14.04% (16/114) of the tumors (Table 4).
Table 1 Ultrasound and contrast-enhanced ultrasonography of hepatic epithelioid angiomyolipoma

| Items                                      | Cases          |
|--------------------------------------------|----------------|
| Ultrasound                                 |                |
| Echo (low/mixed/high)                      | 54/8/24        |
| Internal uniformity (heterogeneity/homogeneity) | 37/38          |
| Boundary (clear/indistinct)                | 55/5           |
| Hypoechoic halo (Y/N)                      | 13/34          |
| Blood supply (rich/abundant/rare)          | 22/6/7         |
| Contrast-enhanced ultrasonography          |                |
| Arterial phase (high/middle/low)           | 15/0/0         |
| Portal phase (high or slightly high/middle/low or slightly low) | 4/8/3   |
| Delay phase (high or slightly high/middle/low or slightly low) | 3/7/5   |

Microscope appearance: Epithelioid tumor cells could be observed under the microscope and arranged irregularly in nodules or flaky structures, with relatively obvious atypia. Sometimes multinucleated giant cells and ganglion-like large cells could be observed. Generally, epithelioid tumor cells were round, polygonal, or short-spindle in shape and were radially distributed around thin-walled blood vessels or muscular arteries. The cytoplasm was abundant and slightly eosinophilic staining. Sometimes the cytoplasm was clear and contained adipose vacuoles. The centrally located nuclei were large, round, or oval in shape. The nucleoli were obvious and mitotic figures were rare.

Immunohistochemistry: Immunohistochemical examination revealed that the expressions of HMB45, SMA, Actin, Melan-A, macrophage marker 387, melanoma antigen recognized by T-cells 1, A103, etc were positive. The expressions of CD31, CD34 on vascular wall, vimentin, pp70S6K, and MyoD1 were positive in about half of the cases. In a few cases, the fat S-100, CD68, desmin, muscle specific actin, human myeloperoxidase (MPO), E-cadherin, and b-cadherin was positive or weakly positive. The Kpan, AFP, HepPar-1, EMA, CEA, CD117, and p53 was basically negative (Table 5). The Ki-67 expression ranged from < 1% to 15%, with a median of 1.96%.

Follow-up: The duration of follow-up was 2 mo to 180 mo, with a median of 31 mo. The rate of malignancy was 3.96% (16/409). Notably, among the 16 malignant cases, only 1 case was diagnosed potential malignancy on pathology, other cases were identified malignancy because of intrahepatic recurrence (6 cases) and distant metastases (9 cases). Among those metastatic cases, 2 cases were lung metastasis and 1 case was bone metastasis, while other cases were not specified the sites of metastasis. The time of postoperative relapse was 5 mo to 108 mo, with a median of 42.5 mo.

Discussion

Since Bonetti and colleagues first described AML in 1992, it has gradually been increasingly recognized as a relatively rare mesenchymal tumor. AML was most commonly found in the kidney and less often in the liver. Most patients with hepatic AML were female and asymptomatic, and the masses usually occurred in non-cirrhotic liver without serological abnormalities. In most cases, hepatic AML was discovered incidentally during regular health check-ups or examinations for other diseases. The pathogenesis of hepatic AML has not yet been clarified. There was an association with TSC in more than 50% of the AML in the kidney, but this association had been estimated to be only 5%-15% of the patients presenting with solitary liver tumors. In our review, TSC was found in 7 patients (1.7%), which might be underestimated due to incomplete information. However, TSC was probably a risk factor for malignant behavior of epithelioid AML. Histologically, it was composed of blood vessels, adipose tissue, and smooth muscle. Compared with typical AML, HEAML was histologically dominated by epithelioid cells and contained much less adipose cells.

HEAML occurred primarily in young and middle-aged females, with an average age of 45 years old at the time of diagnosis. The male to female ratio was about 1:4.84. Approximately two-thirds of patients were found to be asymptomatic on physical examination, while one-third of patients presented with discomfort or swelling pain of the epigastrium or right upper quadrant. A few patients presented with an abdominal mass, poor appetite, nausea and vomiting, anemia, fatigue, low fever,
weight loss, changes in bowel habits, etc. Patients usually had no hepatitis, cirrhosis, or family history of this type of tumor. The common tumor markers were almost all negative.

HEAML imaging findings included: (1) Most of the tumors were solitary and round in morphology, while a few were lobulated or irregular, with clear boundaries; (2) Ultrasound scan indicated low echo with internal nonuniformity, clear boundary, and rich blood supply in most cases, sometimes with low echo halo. Contrast-enhanced ultrasound showed that all lesions appeared homogeneous hyperechoic during arterial phase, and most lesions appeared homogeneous isoechoic during portal and delayed phase; (3) CT plain scan usually showed low density lesions, which was obviously or moderately enhanced in arterial phase, and the enhancement decreased during portal and delayed phase in most cases; (4) Most of the lesions were accompanied by central vessels and early drainage veins, which afflux into branches of the hepatic vein or portal vein; (5) The enhanced scan showed varied characteristics. The ratio of fast wash-in and fast wash-out, fast wash-in and slow wash-out, and delayed enhancement was roughly 4:5:1; (6) HEAML usually had no capsule. When the tumor was large enough, it might oppress the surrounding liver parenchyma to form an incomplete pseudocapsule. Recognizing the imaging features of no capsule, and hypervasularity with central punctiform or filiform vessels as a characteristic enhancement may distinguish Epi-HAML from other hepatic tumors; and (7) MRI scan usually suggested inhomogenous and low T1WI signal, and increase in T2WI and DWI signal. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced scan usually showed marked enhancement in arterial phase, which was decreased during portal and delayed phase.

The preoperative misdiagnosis rate was as high as 40.34% (165/409) because of the non-specific clinical and imaging manifestations of HEAML. It was necessary to differentiate with hepatocellular carcinoma, focal nodular hyperplasia, HCA, hemangiomas, and metastatic cancers when making diagnosis. Currently, the major treatment strategy was surgical resection. In general, HEAML had no capsule, but presented with clear boundaries. HEAML demonstrated expansive growth and squeezed the adjacent liver parenchyma. Internal hemorrhage and necrosis was more common than typical AML. The definitive diagnosis of HEAML depended on pathological findings of epithelioid cells in the lesions, and the immunohistochemical findings of melanoma specific markers (HMB45, Melan-A) and myogenic markers (SMA, muscle specific actin, Actin).

Most of the HEAMLs were benign, with a relatively low malignant rate of 3.91% (16/409). Notably, 15 cases of malignancy were identified because of intrahepatic recurrence or distant metastasis, while the pathological examination did not demonstrate malignancy distinctly on the first operation. The malignant HEAML mainly metastasize to the lung and bones and could involve multiple organs in severe cases. The median time of postoperative relapse was 42.5 mo. Therefore, periodic reexamination was needed to prevent recurrence, especially within 5 years after surgery, just like gastrointestinal tumors. In addition, the HEAML could be secondary, with primary lesions mostly originated from kidney. The second case reported in this article initially presented as retroperitoneal lymph node enlargement 1 year after renal EAML resection, and eventually exhibited liver and lung metastases 5 years after the surgery. Secondary HEAML has rarely been reported. Among the 17

---

### Table 2 Preoperative computed tomography manifestations of hepatic epithelioid angiomyolipoma

| Items                                      | Cases     |
|--------------------------------------------|-----------|
| **Computed tomography**                    |           |
| Plain scan phase                           |           |
| Uniformity (uniform/non-uniform)           | 15/24     |
| Density (low density/equidensity)          | 63/9      |
| Arterial phase (Obvious uniform enhancement/apparent or moderate non-uniform enhancement) | 54/53     |
| Portal phase (obvious enhancement/enhancement reduction) | 33/42     |
| Delayed phase (sustained moderate enhancement/enhancement reduction) | 23/30     |
| **Characteristic manifestations**          |           |
| Central vessel sign (Y/N)                  | 119/38    |
| Early drainage veins (Y/N)                 | 75/47     |
| Enhancement mode (fast wash-in and fast wash-out/fast wash-in and slow wash-out/delayed enhancement) | 67/83/15  |
| Pseudocapsule (Y/N)                        | 65/73     |
Table 3 Preoperative magnetic resonance imaging and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced scan manifestations of hepatic epithelioid angiomyolipoma

| Items                                      | Cases                        |
|-------------------------------------------|------------------------------|
| Magnetic resonance imaging                |                              |
| T1WI                                      |                              |
| Low, slightly low signal/equisignal/high signal | 107/1/1                     |
| Slightly uniform/non-uniform              | 13/26                        |
| T2WI                                      |                              |
| Slightly high signal/high signal          | 39/70                        |
| Slightly uniform/non-uniform              | 3/29                         |
| DWI                                       |                              |
| Slightly high signal/high signal          | 13/51                        |
| Slightly uniform/non-uniform              | 4/15                         |
| Gd-EOB-DTPA                               |                              |
| Arterial phase                            |                              |
| Homogeneous enhancement/heterogeneous enhancement | 29/21                      |
| Obvious enhancement/Medium enhancement   | 47/7                         |
| Portal phase                              |                              |
| Continuous enhancement/enhancement weakened | 22/29                      |
| Delayed phase                             |                              |
| Continuous enhancement/enhancement weakened | 1/2                        |

T1WI: T1 weighted imaging; DWI: Diffusion weighted imaging; Gd-EOB-DTPA: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid.

Secondary cases reported\(^{[8,37,66-71]}\), 5 cases turned to multiple metastases. Secondary HEAML had no significant differences from primary HEAML in terms of clinical manifestations, imaging findings, pathology, and immunohistochemistry.
Table 4  Gross appearance of hepatic epithelioid angiomyolipoma

| Items                                | Cases or manifestations                      |
|--------------------------------------|----------------------------------------------|
| Section                              | Mostly incanus, grayish yellow or grayish red|
| Capsule (Y/N)                        | 10/53                                        |
| Boundary                             | Clear                                        |
| Texture (slightly soft/medium/slightly dense) | 65/6/18                                      |
| Hemorrhage or necrosis (Y/N)         | 60/89                                        |
| Fat lesions (Y/N)                    | 23/46                                        |
| Cystic degeneration (Y/N)            | 16/98                                        |

Table 5  Immunohistochemistry markers of hepatic epithelioid angiomyolipoma

| Markers   | Positive/weakly positive/negative (+/±/-) | Positive rate |
|-----------|------------------------------------------|---------------|
| HMB45     | 219/2/5                                  | 97.35%        |
| S-100     | 19/5/63                                  | 24.71%        |
| SMA       | 128/15/32                                | 77.43%        |
| MSA       | 4/10/1                                   | 60%           |
| Actin     | 32/1/5                                   | 85.53%        |
| Melan-A   | 91/1/22                                  | 80.70%        |
| CD31      | 2/0/2                                    | 50%           |
| CD34      | 38/0/34                                  | 52.78%        |
| CD68      | 2/6/5                                    | 33.33%        |
| CD117     | 0/0/13                                   | 0%            |
| Vimentin  | 23/11/17                                 | 55.88%        |
| Kpan      | 0/0/101                                  | 0%            |
| HepPar-1  | 0/0/52                                   | 0%            |
| MAC387    | 6/0/0                                    | 100%          |
| EMA       | 0/0/30                                   | 0%            |
| Desmin    | 0/20/30                                  | 20%           |
| MART-1    | 24/0/1                                   | 96%           |
| CEA       | 1/0/9                                    | 10%           |
| AFP       | 0/1/66                                   | 0.75%         |
| MPO       | 0/1/1                                    | 25%           |
| p53       | 0/0/9                                    | 0%            |
| E-cadherin, b-cadherin               | 0/1/4                                      | 10%           |
| pp70S6K   | 1/2/1                                    | 50%           |
| MyoD1     | 2/2/1                                    | 60%           |

HMB45: Human melanoma black 45; SMA: Smooth muscle actin; MSA: Muscle specific actin; Melan-A: Melanoma antigen; EMA: Epithelial membrane antigen; CEA: Carcino-embryonic antigen; AFP: Alpha fetoprotein; MPO: Human myeloperoxidase.

ACKNOWLEDGEMENTS

We thank the patients for their cooperation. We thank Dr. Qing-Zi Zhu (Department of Pathology, Changzheng Hospital) for supplying HEAML tissue.

REFERENCES

1. Ma ZP, Lin GS, Chen BY, Wang C, Zhou JJ. MRI and clinical analysis of hepatic epithelioid angiomyolipoma. Zhonghua Shiyong Zhenduan Yu Zhiliao Zazhi 2018; 32: 172-175 [DOI: 10.13507/j.issn.1674-3474.2018.02.020]  
2. Lee SY, Kim BH. Epithelioid angiomyolipoma of the liver: a case report. Clin Mol Hepatol 2017; 23: 91-94 [PMID: 28301899 DOI: 10.3350-cmh.2017.0011]  
3. Yang XG, Liu GJ, He ML, Hu YF, Tong QY, Qiu WJ. CT and MRI characteristics of hepatic epithelial
Wu ZJ, Hua H, Chen JJ, Jiang G, Li XF, Li SK, Xu WJ. CT characteristics of hepatic epithelial angiomyolipoma. Zhongguo Chuangsheng Yi Xue Zazhi 2017; 33: 147-149

Liu J, Zhang CW, Hong DF, Tao R, Chen Y, Shang MJ, Zhang YH. Primary hepatic epithelial angiomyolipoma: A malignant potential tumor which should be recognized. World J Gastroenterol 2016; 22: 4906-4917 [DOI: 10.3748/wjg.v22.i20.4908]

Oriti S, Tortosa F. Epithelioid angiomyolipoma of the liver: Clinicopathological correlation in a series of 4 cases. Rev Esp Enferm Dig 2016; 108: 27-30 [PMID: 26765232]

Liu W, Meng Z, Liu H, Li W, Wu Q, Zhang X, E C. Hepatic epithelial angiomyolipoma is a rare and potentially severe but treatable tumor: A report of three cases and review of the literature. Oncol Lett 2016; 11: 3669-3675 [DOI: 10.3748/ol.1602.1444]

Fukuda Y, Omiya H, Takami K, Mori K, Kodama Y, Mano M, Nomura Y, Akiha I, Yano H, Nakashima O, Ogasawara M, Mita E, Nakamori S, Sekimoto M. Malignant hepatic epithelial angiomyolipoma with recurrence in the lung 7 years after hepatectomy: a case report and literature review. Surg Case Rep 2016; 2: 31 [PMID: 27037804] DOI: 10.1186/s40792-016-0158-1.

Liu LX, Xie LQ. Diagnosis of hepatic epithelial angiomyolipoma: one case report and review of literature. Yi Xue Yingxiangxue Zazhi 2016; 26: 753-755

Wu RD, Yang XF, Wang M, Zhou LS, Huang K, Fang ZN, Zeng KG, Feng ST. Hepatic Epithelial Angiomyolipoma MSCT Findings. Lincunzhang Fangshexue Zazhi 2016; 35: 395-398 [DOI: 10.13437/cjnci.jz.2016.03.023]

Song X, Xu SL, Xiao WB. CT and MRI manifestations of hepatic epithelial angiomyolipomas. Zhongguo Yi Xue Yingxiang Zazhi 2016; 32: 87-90 [DOI: 10.13892/j.1003-3289.2016.01.023]

Yu YH, Wu JT, Wang SA. Imaging features of hepatic epithelial angiomyolipoma. Yiliao Weisheng Zhanqubei 2016; 37: 75-77 [DOI: 10.6878] ISSN0013-8868 2016.03.075]

Huang SC, Chuang HC, Chen TD, Chi CL, NgKF, Yeh TS, Chen TC. Alterations of the mTOR pathway in hepatic epithelioid angiomyolipoma with emphasis on the epithelioid variant and loss of heterogeneity of TSC1/TSC2. Histopathology 2015; 66: 695-705 [PMID: 25324729 DOI: 10.1111/his.12551]

Sun J, Wang S, Chen W, Wu J. Gid-FOB-DTPA-enhanced and diffusion-weighted magnetic resonance findings in hepatic epithelioid angiomyolipoma: A case report. Oncol Lett 2015; 10: 1145-1148 [PMID: 26622641] DOI: 10.3892/ol.2015.3368]

Tang YQ, Li JW, Ling WW, Ling L, Qiu GJ, Yan L. Features of hepatic epithelioid angiomyolipoma on ultrasonography. Zhongguo Yi Xue Yingxiang Zazhi 2015; 31: 746-749 [DOI: 10.13892/j.1003-3289.2015.05.027]

Mei HY, Wang SY. Imaging diagnosis of epithelioid angiomyolipoma of liver. Shiyong Yixue Yingshi Zazhi 2015; 2: 154-156 [DOI: 10.16106/cjnci.cn14-1281-r.2015.02.023]

Wu QQ, Chen ZQ. Imaging findings and pathologic correlation of hepatic epithelioid angiomyolipoma. Yi Xue Yingxiangxue Zazhi 2015; 4: 662-665

Zhang JW, Xu PJ. Epithelioid Angiomyolipoma of the Liver: Analysis of Magnetic Resonance Imaging Features. Zhongguo Yi Xue Jiashi Chengxiang Zazhi 2015; 21: 124-128 [DOI: 10.19627/j.cnki.cn31-1700/th.2015.02.009]

Barbier L, Torrents J, Hardwigsen J. Hepatic angiomyolipoma: what management? Acta Chir Belg 2014; 114: 139-142 [PMID: 25073214] DOI: 10.1002/ijc.2016.11.009]

Dai CL, Mei HY, Zeng KG, Feng ST. Hepatic Epithelial Angiomyolipoma: Pitfall of misdiagnosis. World J Gastroenterol 2014; 20: 3364-3368 [PMID: 24696616] DOI: 10.3748/wjg.v20.i12.3364

Tajima S, Suzuki A, Suzumura K. Ruptured hepatic epithelioid angiomyolipoma: a case report and literature review. Case Rep Oncol 2014; 7: 369-375 [PMID: 24987338] DOI: 10.11016/j.cronc.2013.05.009]

Xu H, Wang H, Zhang X, Li G. [Hepatic epithelioid angiomyolipoma: a clinicopathologic analysis of 25 cases]. Zhonghua Bing Li Xue Za Zhi 2014; 43: 685-689 [PMID: 25567596]

Zhao Y, Ou Yang H, Wang X, Ye F, Liang J. MRI manifestations of epithelioid and nonepithelioid angiomyolipoma. J Magn Reson Imaging 2014; 39: 1502-1508 [PMID: 24129971] DOI: 10.1002/jmri.24291]

Zhou Y, Chen F, Wang W, Miao Q, Wang F. Hepatic epithelioid angiomyolipoma with an unusual pathologic appearance: expanding the morphologic spectrum. Int J Clin Exp Pathol 2014; 7: 6364-6369 [PMID: 25337202]

Zhao Y, Zheng XL, Wei M, Center MI. MRI Diagnosis of Hepatic Angiomyolipoma. Zhongguo CT He MRI Zazhi 2014; 3: 75-77 [DOI: 10.3969/j.issn.1672-5131.2014.03.021]

Occhionorelli S, Dellachiesa L, Stano R, Cappellari I, Tartarini D, Severi S, Palmini G, Pansini GC, Vasquez G. Spontaneous rupture of a hepatic epithelioid angiomyolipoma: damage control surgery. A case report. G Chir 2013; 34: 320-322 [PMID: 2342160]

Kang SL, He B, Han D. One case: lipid-poor hepatic epithelioid angiomyolipoma of the male. Shiyong Fangshexue Zazhi 2013; 29: 338-339

Ju JS, Lu CY, Wang ZF, Xu M, Song JJ. Epithelioid angiomyolipoma of the liver: CT and MRI features. Abdom Imaging 2013; 38: 309-314 [PMID: 22610058] DOI: 10.1007/s00261-012-9911-3]

Lo RC. Epithelioid angiomyolipoma of the liver: a clinicopathological study of 5 cases. Ann Diagn Pathol 2013; 17: 412-415 [PMID: 23766777] DOI: 10.1016/j.anndiagpath.2013.04.009]

Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Sugimoto K, Iwashashi Y, Yamada S, Asanoma M, Ishibashi H. Hepatic epithelioid angiomyolipoma with arterioporal venous shunting mimicking hepatocellular carcinoma: report of a case. J Med Invest 2013; 60: 262-266

Li FQ, Qian HF, Zhu YM, Ding Y, Hu XH. Diagnosis of Hepatic Epithelioid Angiomyolipoma by MRI. Yi Xue Yanjiu Zazhi 2013; 42: 164-167 [DOI: 10.3969/j.issn.1673-548X.2013.03.051]

Wu ZJ, Hua H, Chen JT, Jiang G, Li XF, Li SK, Xu WJ. CT characteristics of hepatic epithelioid angiomyolipoma. Zhongguo Yi Xue Yingxiang Zazhi 2013; 29: 84-87 [DOI: 10.13926/j.1003-3289.2013.01.041]
A series of six cases with emphasis on pathological-radiological correlations and unusual variants diagnosed by core needle biopsy.

Int J Clin Exp Pathol 2012; 5:12-121.

Limaiani F, Korbi S, Lahmar A, Bourouai S, Allou S, Jedidi S, Miloudi N, Mzab-Regaya S. A misleading hepatic tumour: epithelioid angiomyolipoma. Acta Gastroenterol Belg 2012; 75: 443-445

Mao JX, Lin H. Hepatic Epithelioid Angiomyolipoma One Case Report of Ultrasonography and Review of Literature. Hanshuo Jibing Zazhi 2012; 19: 34-37 [DOI: 10.3968/j.issn.1009-3257.2012.04.010]

Liu JP, Chen ZJ, Huang YY, Sun ZS, Lu CY. Imaging and pathological features of hepatic monotypic epithelioid angiomyolipoma. Xingye Xingyi Shaozhe Xue 2012; 22: 219-221 [DOI: 10.3969/j.issn.1674-5671.2011.02.027]

Xie L, Jessuran J, Manivel JC, Pambuccian SE. Hepatic epithelioid angiomyolipoma with trabecular growth pattern: a mimic of hepatocellular carcinoma on fine needle aspiration cytology. Diagn Cytopathol 2010; 40: 639-650 [PMID: 21563318 DOI: 10.1002/dc.21701]

Liu H, Zhou BY, Lin H. Hepatic Epithelioid Angiomyolipoma: Two Cases Report and Literature Review. Liaohuang Fangshexue Zazhi 2012; 31: 1805-1807

Talati H, Radhi J, Popovich S, Marcaccio M. Epithelial Angiomyolipoma: Case Series. Gastroenterology Res 2010; 3: 293-295 [PMID: 27942412 DOI: 10.4021/52736]

Ma HL, Yang CB, Chen WB, Zhang WJ, Li L. Hepatic epithelioid angiomyolipoma: an analysis of two cases. Shijie Huaren Xuehuan Zazhi 2011; 19: 1071-1074 [DOI: 10.11569/wcj.v19.i10.1071]

Zhang B, LV ZL, Qin X, Peng MH, Peng T. Hepatic epithelioid angiomyolipoma: A case report and literature review. Zhongguo Aizheng Fangzhi Zazhi 2011; 3: 120-125 [DOI: 10.3969/j.issn.1674-5671.2011.02.07]

Wang ZH, Wu D, Hou J, Zhang LT, Kong QK. MRI diagnosis of epithelioid angiomyolipoma of liver. Zhonghua Fangshexue Zazhi 2012, 46: 803-806 [DOI: 10.3760/cma.j.issn.1005-1201.2012.09.007]

Zhang LP, Tang HH, Li LC, Li FY, He YQ, Wu RG, Huang H, Huang DC. CT Features of Epithelioid Angiomyolipoma in Liver: Report of 2 Cases and Literature Review. Linchuang Fangshexue Zazhi 2012; 26: 973-976 [DOI: 10.3969/j.issn.1002-1671.2010.07.014]

Alatassi H, Sahoo S. Epithelioid angiomyolipoma of the liver with striking giant cell component: fine-needle aspiration biopsy findings of a rare neoplasm. Diagn Cytopathol 2009; 37: 192-194 [PMID: 19156824 DOI: 10.1002/dc.200979]

Yamasaki S, Tanaka S, Fujii H, Matsumoto T, Okuda C, Watanabe G, Suda K. Monotypic epithelioid angiomyolipoma of the liver. Histopathology 2000; 36: 451-456 [PMID: 10792487 DOI: 10.1046/j.1365-2559.2000.00884.x]

Leeneman EE, Mukhina MS, Nasyrov AR. [Monophasic angiomyolipoma (PEComa) of the liver]. Arch Pathol 2009; 71: 44-46 [PMID: 20131508]

Xu PJ, Shan Y, Yan FH, Ji Y, Ding Y, Zhou ML. Epithelioid angiomyolipoma of the liver: cross-sectional imaging findings of 10 immunohistochemically-verified cases. World J Gastroenterol 2009; 15: 4576-4581 [PMID: 19777618 DOI: 10.3748/wjg.v15.i15.4576]

Yuan Y, Zhang J, Huang YN. One case report of epithelioid angiomyolipoma (EAML) of liver. Xixian Zhongguo Xue 2009; 17: 1776-1780

Deng YF, Lin Q, Zhang SH, Ling YM, He JK, Chen XF. Malignant epithelioid angiomyolipoma in the liver: a case report with pathological and molecular analysis. Pathol Res Pract 2008; 204: 911-918 [PMID: 18723294 DOI: 10.1016/j.prp.2008.08.007]

Khalibuss WE, Fischer G, Bazooaband A. Imprint cytology of epithelioid hepatic angiomyolipoma: mimegrity of hepatocellular carcinoma. Acta Cytol 2007; 51: 670-672 [PMID: 17718152]

Parfit JR, Bella AJ, Iawa JJ, Wehrli BM. Malignant neoplasm of peripheral epithelioid cells of the liver. Arch Pathol Lab Med 2006; 130: 1219-1222 [PMID: 16879028 DOI: 10.1045/1543-2165(2006)130[1219:MNOPEC]2.0.CO;2]

Rouquie D, Eggenpsieler P, Algayres JP, Béchade D, Camparo P, Baranger B. [Malignant-like angiomyolipoma of the liver: report of one case and review of the literature]. Am Cheir 2006; 31: 338-341 [PMID: 16336232 DOI: 10.1016/0005-8540(56)90005-8]

Mizuguchi T, Katsumaki T, Nobuoka T, Nishikage A, Oshima H, Kawasaki H, Kimura S, Sato H, Hiraoka T. Growth of hepatic angiomylipoma indicating malignant potential. J Gastroenterol Hepatol 2004; 19: 1328-1330 [PMID: 15482547 DOI: 10.1111/j.1440-1746.2004.03583.x]

Tryggvason G, Blöndal S, Goldin RD, Albrechtsson J, Björnsson J, Jónasson JEG. Epithelioid angiomyolipoma of the liver: case report and review of the literature. APDMIS 2004; 112: 122-126 [PMID: 15601311 DOI: 10.1111/j.1606-4603.2004.apm12009.x]

Hino A, Hirokawa M, Takamura K, Sano T. Imprint cytology of epithelioid angiomyolipoma in a patient with tuberous sclerosis. Acta Cytol 2002; 46: 545-549 [PMID: 12040651 DOI: 10.1016/s0001-7085(02)00079-1]

Lin Y, Shi Q, Zhou X. Hepatic monotypic epithelioid angiomyolipoma: two cases report and review of literature. Zhenduan Bingliuxue Zazhi 2002; 9: 281-276 [DOI: 10.1109/s0731-7085(02)00079-1]

Mai KT, Yazdi HM, Perkins DG, Thijssen A. Fine needle aspiration biopsy of epithelioid angiomyolipoma. A case report. Acta Cytol 2001; 45: 233-236 [PMID: 11284309]

Croquet V, Pilellet C, Aubé C, Bouju B, Oberti F, Cervi C, Arnaud JP, Rousselet MC, Boyer J, Calès P. Late recurrence of a hepatic angiomylipoma. Eur J Gastroenterol Hepatol 2000; 12: 579-582 [PMID: 10833105 DOI: 10.1080/095413300205000018]

Dalle I, Scro R, de Vos R, Aerts R, van Damme B, Desmet V, Roskams T. Malignant angiomyolipoma of the liver: a hitherto unreported variant. Histopathology 2000; 36: 443-450 [PMID: 10792486 DOI: 10.1046/j.1365-2559.2000.00991.x]

Flemming P, Lehmann U, Becker T, Klempauer J, Kreipe H. Common and epithelioid variants of hepatic angiomyolipoma exhibit clonal growth and share a distinctive immunophenotype. Hepatology 2000; 32: 213-217 [PMID: 10915726 DOI: 10.1053/heap.2000.9142]

Savastano S, Piotto M, Magnelli R, Spanio P, Rubbelletti L. A monotypic variant of hepatic angiomylipoma completely composed of perivascular epithelioid cells. A case. Radiol Med 2000; 100: 82-87
65 Klompenhouwer AJ, Verver D, Janki S, Bramer WM, Doukas M, Dwarkasing RS, de Man RA, IJzermans JNM. Management of hepatic angiomyolipoma: A systematic review. Liver Int 2017; 37: 1272-1280 [PMID: 28177183 DOI: 10.1111/liv.13381]

66 Guo B, Song H, Yue J, Li G. Malignant renal epithelioid angiomyolipoma: A case report and review of the literature. Oncol Lett 2016; 11: 95-98 [PMID: 26870174 DOI: 10.3892/ol.2015.3846]

67 Neofytou K, Fanuloro S, Khan AZ. PEComa in a Young Patient with Known Li-Fraumeni Syndrome. Case Rep Med 2015; 2015: 906981 [PMID: 25821471 DOI: 10.1155/2015/906981]

68 Vicens RA, Jensen CT, Korivi BR, Bhosale PR. Malignant renal epithelioid angiomyolipoma with liver metastasis after resection: a case report with multimodality imaging and review of the literature. J Comput Assist Tomogr 2014; 38: 574-577 [PMID: 24887578 DOI: 10.1097/RCT.0000000000000101]

69 Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hess O, Svec A, Kida M, Vankalakunti M, Berel D, Rogatko A, Gown AM, Amin MB. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011; 35: 161-176 [PMID: 21263237 DOI: 10.1097/PAS.0b013e318206f2a0]

70 Sato K, Ueda Y, Tachibana H, Miyazawa K, Chikazawa I, Kaji S, Nojima T, Katsuda S. Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis. Pathol Res Pract 2008; 204: 771-777 [PMID: 18547741 DOI: 10.1016/j.prp.2008.04.008]

71 Lin WC, Wang JH, Wei CJ, Pan CC, Chang CY. Malignant renal epithelioid angiomyolipoma with aggressive behavior and distant metastasis. J Chin Med Assoc 2003; 66: 303-306 [PMID: 12908574]
